Basic mechanisms of urgency: roles and benefits of pharmacotherapy

Martin Christian Michel, Christopher R Chapple, Martin Christian Michel, Christopher R Chapple

Abstract

Introduction: Since urgency is key to the overactive bladder syndrome, we have reviewed the mechanisms underlying how bladder filling and urgency are sensed, what causes urgency and how this relates to medical therapy.

Materials and methods: Review of published literature.

Results: As urgency can only be assessed in cognitively intact humans, mechanistic studies of urgency often rely on proxy or surrogate parameters, such as detrusor overactivity, but these may not necessarily be reliable. There is an increasing evidence base to suggest that the sensation of ‘urgency’ differs from the normal physiological urge to void upon bladder filling. While the relative roles of alterations in afferent processes, central nervous processing, efferent mechanisms and in intrinsic bladder smooth muscle function remain unclear, and not necessarily mutually exclusive, several lines of evidence support an important role for the latter.

Conclusions: A better understanding of urgency and its causes may help to develop more effective treatments for voiding dysfunction.

References

    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178. doi: 10.1002/nau.10052.
    1. Michel MC, Chapple CR. Basic mechanisms of urgency: basic and clinical evidence. Eur Urol. 2009
    1. Oliver S, Fowler C, Mundy A, et al. Measuring the sensation of urge and bladder filling during cystometry in urge incontinence and the effect of neuromodulation. Neurourol Urodyn. 2003;22:7–16. doi: 10.1002/nau.10082.
    1. Lowenstein L, Fitzgerald MP, Kenton K, et al. Validation of a real-time urodynamic measure of urinary sensation. Am J Obstet Gynecol. 2008;198:661.e1–661.e5. doi: 10.1016/j.ajog.2008.02.023.
    1. Wyndaele J-J, van Meel TD, de Wachter S. Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J Urol. 2004;172:1915–1918. doi: 10.1097/01.ju.0000142429.59753.5c.
    1. Malone-Lee J, Henshaw DJE, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int. 2003;92:415–417. doi: 10.1046/j.1464-410X.2003.04351.x.
    1. Rovner E, Payne C, Yalla S et al (2005) Response to fesoterodine in overactive bladder (OAB) patients is independent of the uryodynamic finding of detrusor overactivity.
    1. Matharu G, Donaldson MMK, McGrother CW, et al. Relationship between urinary symptoms reported in a postal questionnaire and urodynamic diagnosis. Neurourol Urodyn. 2005;24:100–105. doi: 10.1002/nau.20093.
    1. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175:191–195. doi: 10.1016/S0022-5347(05)00067-4.
    1. Haylen BT, Chetty N, Logan V, et al. Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity? Int Urogynecol J. 2007;18:123–128. doi: 10.1007/s00192-006-0165-z.
    1. de Wachter S, van Meel TD, Wyndaele J-J. Can a faked cystometry deceive patients in their perception of filling sensations? A study on the reliability of spontaneous reported cystometric filling sensations in patients with non-neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2008;27:395–398. doi: 10.1002/nau.20523.
    1. Morrison J, Birder LA, Craggs M, et al. Neural control. Plymouth: Plymbridge Distributors Ltd; 2006. pp. 363–422.
    1. Morrison J. The activation of bladder wall afferent nerves. Exp Physiol. 1999;84:131–136.
    1. Lips KS, Wunsch J, Sarghooni S, et al. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol. 2007;51:1042–1053. doi: 10.1016/j.eururo.2006.10.028.
    1. Yoshida M, Masunaga K, Satoji Y, et al. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci. 2008;106:193–198. doi: 10.1254/jphs.FM0070115.
    1. Yoshimura N, Kaiho Y, Miyazato M, et al. Therapeutic targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:437–448. doi: 10.1007/s00210-007-0209-z.
    1. Fitzgerald MP, Kenton KS, Brubaker L. Localization of the urge to void in patients with painful bladder syndrome. Neurourol Urodyn. 2005;24:633–637. doi: 10.1002/nau.20177.
    1. Bulmer P, Abrams P. The unstable detrusor. Urol Int. 2004;72:1–12. doi: 10.1159/000075265.
    1. Athwal BS, Berkley KJ, Hussain I, et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain. 2001;124:369–377. doi: 10.1093/brain/124.2.369.
    1. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27:466–474. doi: 10.1002/nau.20549.
    1. Andersson K-E. New pharmacological targets for the treatment of the overactive bladder: an update. Urology. 2004;63(Suppl 3A):32–41. doi: 10.1016/j.urology.2003.10.005.
    1. Kono M, Nakamura Y, Ishiura Y, et al. Central muscarinic receptor subtypes regulating voiding in rats. J Urol. 2006;175:353–357. doi: 10.1016/S0022-5347(05)00004-2.
    1. Cucchi A, Quaglini S, Siracusano S, et al. Urgency degree and bladder contraction velocity: sequential changes in women with idiopathic detrusor overactivity. Neurourol Urodyn. 2006;25:123–127. doi: 10.1002/nau.20217.
    1. Cucchi A, Quaglini S, Rovereto B. Relationships between micturition urgency and involuntary voiding dynamics in men with urinary incontinence from idiopathic detrusor overactivity. J Urol. 2007;178:563–567. doi: 10.1016/j.juro.2007.03.122.
    1. Schneider T, Fetscher C, Krege S, et al. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004;309:1148–1153. doi: 10.1124/jpet.103.063735.
    1. Frazier EP, Peters SLM, Braverman AS, et al. Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:449–462. doi: 10.1007/s00210-007-0208-0.
    1. Rapp DE, Lyon MB, Bales GT, et al. A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol. 2005;48:303–308. doi: 10.1016/j.eururo.2005.04.019.
    1. Sibley GN. A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J Physiol (Lond) 1984;354:431–443.
    1. Fry CH, Wu C, Mundy AR. Bladder instability and detrusor smooth muscle function. Exp Physiol. 1999;84:161–169.
    1. Fry CH, Skennerton D, Wood D, et al. The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urology. 2002;59(Suppl 5A):3–12. doi: 10.1016/S0090-4295(01)01632-6.
    1. Peters SLM, Schmidt M, Michel MC. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci. 2006;27:492–497. doi: 10.1016/j.tips.2006.07.002.
    1. Fry CH. Experimental models to study the physiology, pathophysiology and pharmacology of the lower urinary tract. J Pharmacol Toxicol Methods. 2004;49:201–210. doi: 10.1016/j.vascn.2004.03.002.
    1. Coolsaet BL, van Duyl WA, van Os-Bossagh P, et al. New concepts in relation to urge and detrusor overactivity. Neurourol Urodyn. 1993;12:463–471. doi: 10.1002/nau.1930120504.
    1. Drake MJ, Harvey IJ, Gillespie JI, et al. Localized contractions in the normal human bladder and in urinary urgency. BJU Int. 2005;95:1002–1005. doi: 10.1111/j.1464-410X.2005.05455.x.
    1. Elbadawi A, Meyer S. Morphometry of the obstructed detrusor. I. Review of the issues. Neurourol Urodyn. 1989;8:163–171. doi: 10.1002/nau.1930080209.
    1. Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165:245–248. doi: 10.1097/00005392-200101000-00072.
    1. Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther. 2008;117:297–312. doi: 10.1016/j.pharmthera.2007.12.001.
    1. Abrams PH, Farrar DJ, Turner-Warwick RT, et al. The results of prostatectomy: a symptomatic and urodynamic analysis in 152 patients. J Urol. 1979;121:640–642.
    1. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–562. doi: 10.1016/j.eururo.2008.06.047.
    1. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–764. doi: 10.1016/j.eururo.2008.06.080.
    1. Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn. 2007;26:190–195. doi: 10.1002/nau.20367.
    1. Starkman JS, Dmochowski RR. Urgency assessment in the evaluation of overactive bladder (OAB) Neurourol Urodyn. 2008;27:13–21. doi: 10.1002/nau.20472.
    1. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45:420–429. doi: 10.1016/j.eururo.2004.01.008.
    1. Steers WD, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005;95:580–586. doi: 10.1111/j.1464-410X.2005.05343.x.
    1. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71:839–843. doi: 10.1016/j.urology.2007.12.017.
    1. Chapple C, van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204–1212. doi: 10.1016/j.eururo.2007.07.009.
    1. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178:2488–2494. doi: 10.1016/j.juro.2007.08.033.
    1. Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100:579–587. doi: 10.1111/j.1464-410X.2007.07031.x.
    1. Chapple CR, Arano P, Bosch JLHR, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93:71–77. doi: 10.1111/j.1464-410X.2004.04561.x.
    1. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–310. doi: 10.1111/j.1464-410X.2004.04606.x.
    1. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919–1924. doi: 10.1097/01.ju.0000140729.07840.16.
    1. Gittelman MC. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int J Gynaecol Obstet. 2003;83(Suppl 3):94.
    1. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328–332. doi: 10.1016/j.urology.2006.03.006.
    1. Khullar V, Hill S, Laval K-U, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology. 2004;64:269–275. doi: 10.1016/j.urology.2004.02.029.
    1. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171:2311–2315. doi: 10.1097/01.ju.0000127742.73136.0c.
    1. Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol. 2003;102:605–611. doi: 10.1016/S0029-7844(03)00623-9.
    1. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol. 2005;173:1214–1218. doi: 10.1097/01.ju.0000155798.78911.57.
    1. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int. 2005;95:591–596. doi: 10.1111/j.1464-410X.2005.05345.x.
    1. Zinner N, Harnett M, Sabounjian L, et al. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol. 2005;173:1639–1643. doi: 10.1097/01.ju.0000154692.73129.d8.
    1. Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol. 2007;51:1054–1064. doi: 10.1016/j.eururo.2006.10.005.
    1. Nitti VW, Dmochowski R, Appell RA, et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int. 2006;97:1262–1266. doi: 10.1111/j.1464-410X.2006.06146.x.
    1. Michel MC, de la Rosette JJMCH, Piro M, et al. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol. 2005;48:110–115. doi: 10.1016/j.eururo.2004.11.012.
    1. Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84:646–651. doi: 10.1046/j.1464-410x.1999.00251.x.
    1. Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007;100:840–845. doi: 10.1111/j.1464-410X.2007.07162.x.
    1. Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl. 2008;7:239.
    1. Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:287–299. doi: 10.1007/s00210-006-0073-2.
    1. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53:275–287. doi: 10.1016/j.eururo.2007.10.013.
    1. Andersson K-E. LUTS treatment: future treatment options. Neurourol Urodyn. 2007;26:934–947. doi: 10.1002/nau.20500.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner